Edition:
United States

AbbVie Inc (ABBV.N)

ABBV.N on New York Stock Exchange

94.38USD
2:14pm EDT
Change (% chg)

$-0.99 (-1.04%)
Prev Close
$95.37
Open
$95.35
Day's High
$96.05
Day's Low
$92.92
Volume
490,118
Avg. Vol
1,726,801
52-wk High
$125.84
52-wk Low
$83.25

Chart for

About

AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology,... (more)

Overall

Beta: 1.54
Market Cap(Mil.): $144,416.20
Shares Outstanding(Mil.): 1,514.27
Dividend: 0.96
Yield (%): 4.03

Financials

  ABBV.N Industry Sector
P/E (TTM): 22.26 29.91 32.14
EPS (TTM): 4.29 -- --
ROI: 13.82 12.97 12.66
ROE: 517.77 14.97 14.84

AbbVie reaches tentative settlement in AndroGel litigation

U.S. drugmaker AbbVie has reached a tentative settlement in multidistrict litigation in Chicago over whether it failed to warn consumers that its testosterone replacement drug AndroGel could cause health problems including heart attacks and strokes.

Sep 11 2018

AbbVie doubles down on cancer project with biotech group Argenx

BRUSSELS Biotech group Argenx said on Wednesday U.S. pharma group AbbVie had exercised an exclusive option to develop and commercialize one of its experimental drugs which could lead to payments of up to $625 million.

Aug 22 2018

AbbVie doubles down on cancer project with biotech group Argenx

BRUSSELS, Aug 22 Biotech group Argenx said on Wednesday U.S. pharma group AbbVie had exercised an exclusive option to develop and commercialise one of its experimental drugs which could lead to payments of up to $625 million.

Aug 22 2018

AbbVie cash cow Humira barely beats sales estimates, stock slides

AbbVie Inc's blockbuster arthritis drug Humira barely beat Wall Street sales forecasts, raising concerns about its future viability as a cash cow and sending the drugmaker's shares down 5 percent on Friday.

Jul 27 2018

UPDATE 2-AbbVie cash cow Humira barely beats sales estimates, stock slides

* Stock down 5 percent in afternoon trade (Adds details from conference call, updates share movement)

Jul 27 2018

AbbVie tops second-quarter estimates, sets higher earnings target

July 27 AbbVie Inc on Friday topped Wall Street estimates for second-quarter profit and raised its yearly earnings forecast, led by stronger demand for top-selling drugs Humira and Imbruvica.

Jul 27 2018

Citron's Left reiterates belief AbbVie shares will fall sharply

NEW YORK Short-seller Andrew Left's Citron Research expanded on his prediction that U.S. drugmaker AbbVie Inc's stock would fall to $60 a share, arguing that new regulations to speed biosimilar drugs to the market and reform rebates will hurt revenue from the company's top-selling drug, Humira.

Jul 24 2018

UPDATE 1-Citron's Left reiterates belief AbbVie shares will fall sharply

NEW YORK, July 24 Short-seller Andrew Left's Citron Research expanded on his prediction that U.S. drugmaker AbbVie Inc's stock would fall to $60 a share, arguing that new regulations to speed biosimilar drugs to the market and reform rebates will hurt revenue from the company's top-selling drug, Humira.

Jul 24 2018

Citron's Left reiterates belief AbbVie shares will fall sharply

NEW YORK, July 24 Short-seller Andrew Left's Citron Research expanded on his prediction that U.S. drugmaker AbbVie Inc's stock would fall to $60 a share, arguing that new regulations to speed biosimilar drugs to the market and reform rebates will hurt revenue from the company's top-selling drug, Humira.

Jul 24 2018

AbbVie prices new endometriosis drug at $10,000 a year

NEW YORK Drugmaker AbbVie Inc priced its new endometriosis drug Orilissa at around $10,000 a year after receiving approval from U.S. regulators for the treatment on Tuesday.

Jul 24 2018

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $140.68 +0.72
Pfizer Inc. (PFE.N) $43.54 +0.54
Novartis AG (NOVN.S) CHF81.46 -0.38
Merck & Co., Inc. (MRK.N) $70.70 +0.28
Roche Holding Ltd. (ROG.S) CHF236.65 -0.40
Roche Holding Ltd. (RO.S) CHF239.80 +0.80
Abbott Laboratories (ABT.N) $68.50 +0.82
Eli Lilly And Co (LLY.N) $106.94 +1.23
Sanofi SA (SASY.PA) €74.90 -0.20

Earnings vs. Estimates